Top Markets
Coin of the day
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Clasificación en acciones #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Precio por acción
$4.74
Última sincronización: 2026-08-31
Capitalización bursátil
$372.19M
Cambio (1 día)
-2.47%
Cambio (1 año)
-1.04%
País
US
Comercio Lexeo Therapeutics, Inc. Common Stock (LXEO)

Categoría

Ratio P/B de Lexeo Therapeutics, Inc. Common Stock (LXEO)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Lexeo Therapeutics, Inc. Common Stock, el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Lexeo Therapeutics, Inc. Common Stock desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.828 -
US
7.5116 -
NL
3.9942 -
AU
8.2199 -
US
- -
CH